Ipsen acquires Kartos Therapeutics for $450 million
French pharmaceutical group Ipsen finalizes the acquisition of US biotech Kartos Therapeutics.
Published 3sem2 sources✓ ConfirmedMajorupdated 2sem
Lire en français
≈ 16s
The fact
The deal, announced on June 28, 2026, strengthens its hematology oncology portfolio.
Kartos retains its Massachusetts headquarters and becomes a wholly-owned subsidiary.
2 sources — click a link to read an article on the topic: